EFG International AG Makes New Investment in DexCom, Inc. $DXCM

Key Points

• EFG International initiated a DexCom position in the second quarter, purchasing 13,201 shares valued at approximately $889,000. Institutional investors collectively own 97.75% of the company.
• Analysts maintain a generally positive outlook, with DexCom receiving a “Moderate Buy” consensus rating and an average price target of $88.71, despite some target-price adjustments.
• DexCom’s latest quarterly results exceeded expectations, with adjusted EPS of $0.70 versus $0.61 estimated and revenue of $1.31 billion, up 13.1% year over year. Shares opened at $88.96, near the company’s 52-week high.

EFG International AG bought a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 13,201 shares of the medical device company's stock, valued at approximately $889,000.

Several other institutional investors also recently made changes to their positions in the stock. BOKF NA grew its position in DexCom by 175.7% during the fourth quarter. BOKF NA now owns 35,314 shares of the medical device company's stock worth $2,344,000 after buying an additional 22,505 shares during the period. Plato Investment Management Ltd purchased a new position in DexCom in the second quarter valued at about $782,000. Stephens Investment Management Group LLC lifted its position in shares of DexCom by 21.1% during the 4th quarter. Stephens Investment Management Group LLC now owns 1,042,801 shares of the medical device company's stock valued at $69,211,000 after acquiring an additional 181,701 shares during the period. Eurizon Capital SGR S.p.A. acquired a new stake in shares of DexCom during the 4th quarter valued at approximately $3,231,000. Finally, Goodman Advisory Group LLC acquired a new stake in shares of DexCom during the 4th quarter valued at approximately $1,293,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, EVP Michael Jon Brown sold 1,700 shares of the company's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $75.55, for a total value of $128,435.00. Following the sale, the executive vice president directly owned 106,353 shares in the company, valued at $8,034,969.15. This represents a 1.57% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kevin R. Sayer sold 26,756 shares of the stock in a transaction on Monday, July 20th. The shares were sold at an average price of $76.32, for a total value of $2,042,017.92. Following the sale, the insider directly owned 328,970 shares in the company, valued at approximately $25,106,990.40. The trade was a 7.52% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 73,035 shares of company stock valued at $5,446,673. 0.28% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on DXCM shares. Bank of America dropped their price objective on DexCom from $100.00 to $80.00 and set a "buy" rating for the company in a research note on Monday, May 18th. TD Cowen reiterated a "buy" rating on shares of DexCom in a research report on Friday, July 31st. Robert W. Baird set a $105.00 target price on DexCom in a report on Friday, July 31st. Stifel Nicolaus set a $95.00 target price on DexCom and gave the company a "buy" rating in a report on Friday, July 31st. Finally, Citigroup restated a "buy" rating and issued a $88.00 price target (up from $84.00) on shares of DexCom in a research report on Friday, July 31st. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $88.71.

DexCom Trading Down 0.2%

Shares of DXCM opened at $88.96 on Thursday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.73 and a quick ratio of 1.43. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $92.59. The stock has a market cap of $33.57 billion, a price-to-earnings ratio of 35.16, a price-to-earnings-growth ratio of 1.50 and a beta of 1.41. The firm has a 50 day simple moving average of $78.50 and a 200-day simple moving average of $71.33.

DexCom (NASDAQ:DXCM - Get Free Report) last posted its earnings results on Thursday, July 30th. The medical device company reported $0.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.61 by $0.09. The firm had revenue of $1.31 billion for the quarter, compared to analyst estimates of $1.29 billion. DexCom had a return on equity of 35.94% and a net margin of 20.12%.DexCom's revenue was up 13.1% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.48 EPS. Equities analysts forecast that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company's offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source